Considerations for the clinical use of teplizumab in stage 2 Type 1 diabetes: A Consensus Statement from the British Society of Paediatric Endocrinology and Diabetes (BSPED) and the Association of British Clinical Diabetologists (ABCD)
Dias, Renuka P Marcovecchio, M Loredana Willemsen, Ruben H Campbell, Fiona Ashour, Ahmad Newland-Jones, Philip Cooper, Jennifer Narendran, Parth Wright, Neil P
Dias, Renuka P
Marcovecchio, M Loredana
Willemsen, Ruben H
Campbell, Fiona
Ashour, Ahmad
Newland-Jones, Philip
Cooper, Jennifer
Narendran, Parth
Wright, Neil P
Abstract
INTRODUCTION: In 2025, the Medicines and Healthcare products Regulatory Agency (MHRA) approved the use of teplizumab (a monoclonal anti-CD3 antibody) to delay progression from Stage 2 to Stage 3 Type 1 diabetes in the UK.
METHODS: To address the need for clear guidance on managing patients eligible for teplizumab therapy, the British Society of Paediatric Endocrinology and Diabetes (BSPED) Type 1 diabetes Special Interest Group (SIG) and the Association of British Clinical Diabetologists (ABCD) assembled a group to review the clinical trial data and develop expert consensus guidelines on the approach to teplizumab infusions.
CONCLUSION: Here, we present recommendations on all aspects of teplizumab administration with evidence base where available. We highlight the safety considerations in individual's selection, screening, monitoring and treatment of potential common side effects.
MIDER Authors
Affiliations
Date
2026-04-29
Type
Article
Collections
Citation
Dias RP, Marcovecchio ML, Willemsen RH, Campbell F, Ashour A, Newland-Jones P, Cooper J, Narendran P, Wright NP. Considerations for the clinical use of teplizumab in stage 2 Type 1 diabetes: A Consensus Statement from the British Society of Paediatric Endocrinology and Diabetes (BSPED) and the Association of British Clinical Diabetologists (ABCD). Diabet Med. 2026 Apr 29:e70329. doi: 10.1111/dme.70329. Epub ahead of print.